LFCM
LAB icon

Long Focus Capital Management’s Standard BioTools LAB Stock Holding History

Long Focus Capital Management’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.7M Buy
16,015,721
+3,337,318
+26% +$4.04M 0.39% 58
2025
Q4 		$16.2M Buy
12,678,403
+1,315,599
+12% +$1.77M 0.43% 54
2025
Q3 		$14.8M Buy
11,362,804
+1,292,804
+13% +$1.69M 0.49% 50
2025
Q2 		$12.1M Buy
10,070,000
+3,370,000
+50% +$3.74M 0.46% 54
2025
Q1 		$7.24M Buy
+6,700,000
New +$9.41M 0.24% 65

Other funds holding LAB

CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HBWM
Hollow Brook Wealth Management Katonah, New York $392M AUM 36.68% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Long Focus Capital Management's LAB Position: Q1 2026 in Review

Long Focus Capital Management increased its Standard BioTools (LAB) stake by 26% in Q1 2026, buying an estimated $4.04M and bringing the position to 16,015,721 shares worth $14.7M. The position accounts for 0.39% of the portfolio, ranked #58.

Long Focus Capital Management first reported a position in LAB in Q1 2025 and has held it in 5 quarters since. The position peaked at $16.2M in Q4 2025. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Long Focus Capital Management held 16,015,721 shares of Standard BioTools worth $14.7M as of Q1 2026.
  • Long Focus Capital Management bought 3,337,318 Standard BioTools shares in Q1 2026, an estimated $4.04M.
  • Standard BioTools made up 0.39% of Long Focus Capital Management's portfolio in Q1 2026, its #58 holding.
  • Long Focus Capital Management first reported a position in Standard BioTools in Q1 2025 and has held it in 5 quarters since.
  • Long Focus Capital Management's Standard BioTools position peaked at $16.2M in Q4 2025.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Long Focus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.